How can a systems biology approach aid precision cancer medicine?

Personalised, genomic-guided combination therapy could transform early disease management in ovarian and breast cancer

What can T-cells see on human cancer?

Moving precision medicine for lung cancer into the adjuvant setting

The importance of target expression in personalised medicine

Ibrutinib combined with bendamustine plus rituximab in previously treated CLL and SLL

TAT 2016: Targeted anticancer therapies

EHA 2015 highlights

Measuring molecular responses to tyrosine kinase inhibitors in chronic myeloid leukaemia

DNMT3A R882 mutations promote chemoresistance and residual disease in AML

Expert overview on the recent developments in mantle cell lymphoma

Round-up of the latest research on lung cancer